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Abstract. The introduction of imatinib, as a type of targeted molecular therapy, has profoundly changed the treatment 
outcome of chronic myeloid leukaemia (CML). The aim of this study was to assess and compare treatment outcome 
among patients who achieved complete cytogenetic response (CCgR) within or after one year following initiation of 
imatinib therapy. A group of 42 adult patients with early chronic-phase Philadelphia-positive CML treated with 
imatinib mesylate therapy has been studied. In the study group CCgR has been achieved in 36/42 (85.71%) analysed 
patients, while in 3/42 (7.14%) patients the absence of cytogenetic response has been noted. Early CCgR has been 
achieved by 25/36 (69.44%) patients with response at median time of 6.91.9 months, while late CCgR has been 
achieved by 11/36 (30.56%) patients at median time of 18.752.4 months. Univariate analysis has identified 
prognostic factors for achieving early and late CCgR. Analysis of remission duration of treatment responders has 
shown that 21/25 (84%) patients in the group with early CCgR and 9/11 (81.81%) patients from the group with late 
CCgR still maintained stable remission on last cytogenetic control. The estimated 5-year survival rate was 85% for 
early responders and 74% for late responders. In conclusion, these results demonstrate that there are no differences 
in the treatment outcome, i.e. level of response, of patients with CML in relation to whether the CCgR was achieved 
within or after one year of imatinib therapy. 
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Introduction 

 
Chronic myeloid leukaemia (CML) is a clonal 
myeloproliferative disease that occurs because of 
constitutive activation of the BCR-ABL tyrosine kinase, 
a result of the t(9;22) (q34;q11) translocation designated 
as the Philadelphia (Ph) chromosome [1]. The 
introduction of the tyrosine kinase inhibitors (TKIs), as 
a type of targeted molecular therapy, has revolutionized 
the management and outlook in CML [2]. The largest 
study up to date that provides the data on the 
effectiveness of imatinib in CML patients is IRIS study. 
It has shown that when imatinib was given as an initial 
treatment of patients in early chronic phase CML, 
complete hematologic response (CHR) after one year 
occurred in 95% of patients and complete cytogenetic 
response (CCgR) in 76%. Of CML patients who 
achieved a CCgR, major molecular response (MMoR) 
was achieved by 57%. After 5 years of treatment, the 
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estimated rate of progression-free survival was 84%, 
and an estimated 93% of patients had not progressed to 
the accelerated phase or blast crisis [3]. Initial studies 
have shown the importance of early achievement of 
therapeutic response, not only achievement of CCgR but 
also MMoR and particularly within the first year of 
therapy, what has been predictive of durable cytogenetic 
remission [4, 5]. Similarly, according to achieving CCgR 
or not at 12 months, the 3-year event free survival rate 
was 98% and 67%, and overall survival was 99% and 
94% [6]. However, another study [7] has shown that there 
was no difference between group of patients with early 
and late achievement of CCgR according to progression-
free survival rate and an estimate 4-year overall survival 
(100% vs. 88% and 100% vs. 92%, respectively). Thus it 
has been demonstrated that it was important to achieve 
CCgR, and that the time of achieving this level of 
response was of less importance. 
The aim of this study was to compare two groups of 
patients with early and late CCgR to determine whether 
there are differences in treatment outcome compared to 
when CCgR was achieved. To explore the difference 
between the two groups based on the time when patients 
achieved CCgR, one year was chosen as the cut-off 
point. This paper presents the examination of the 
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connection between the characteristics of patients before 
treatment and the subsequent possibility of achieving 
early and late CCgR, in order to determine which 
baseline characteristics of patients lead to differences in 
treatment outcome. The probability of maintaining 
CCgR and survival in all patients and in groups with 
early and late CCgR has also been determined. 
Material and Methods 
The analysis included 42 adult patients who were treated 
in our institution with the diagnosis of Ph-positive CML 
in early chronic phase of the disease, during the period 
from 2006 to 2014. In this study patients with CML who 
achieved CCgR to imatinib therapy have been analysed. 
Patients were divided into two groups: the patients who 
achieved CCgR within 1 year (early response) and 
patients in whom CCgR has been achieved after 1 year 
from the beginning of treatment (late response). The 
study analyses the treatment response and survival rate of 
patients in these two groups in order to determine 
whether there are differences in relation to when CCgR 
was achieved. 
The patients have not received prior therapy for 
leukaemia except hydroxyurea which has been conducted 
for initial leukoreduction. All patients started treatment 
with recommended oral dose of imatinib of 400mg once a 
day. Escalated doses of 600mg and 800mg were 
administered in case of failure of previous treatment, 
apropos in patients with cytogenetic relapse or cytogenetic 
refractoriness. 
Chronic phase CML was defined according to the 
recommendations of the LeukaemiaNet panel [8, 9] as 
the presence in the peripheral blood of blasts less than 
15%, basophils less than 20%, blasts together with 
promyelocytes less than 30%, and platelets more than 
100×10
9
/L. After the start of treatment haematological 
and cytogenetic responses have been evaluated in order 
to monitor the response to the treatment. Complete 
blood count and serum chemistry evaluations have been 
performed every month until the CHR was achieved, 
and then every 6 months or in accordance with other 
controls. Marrow studies, including morphologic and 
cytogenetic analysis have been performed every 6 
months to 2 years of therapy, and then every year in 
terms of disclosure of additional chromosomal 
aberrations in case they have achieved stable CCgR. 
Cytogenetic response has been assessed by conventional 
cytogenetics with direct preparation of material from the 
bone marrow with optimal number of mitosis of at least 
20 for assessing response. The response criteria have 
also been defined according to recommendations of the 
LeukaemiaNet panel [8, 9]: complete hematologic 
response (CHR) has been defined as a white blood cell 
count of less than 10×10
9
/L, a platelet count of less than 
450×10
9
/L, the absence of immature cells (blasts, 
promyelocytes, myelocytes) in the peripheral blood, and 
disappearance of all signs and symptoms associated 
with leukaemia (including palpable splenomegaly) for at 
least four weeks. Cytogenetic response has been defined 
as: complete 0% Ph+ cells in metaphase, partial 1%-
35% Ph+ cells in metaphase, minor 36%-65% Ph+ cells 
in metaphase, minimal 66%-95% Ph+ cells in metaphase 
and absent >95% Ph+ cells in metaphase. Major 
cytogenetic response (MCgR) included complete plus 
partial cytogenetic response. 
The results are presented in tables and graphs, 
processed according to the methodology of descriptive 
and analytical statistics. Standard descriptive statistical 
methods (number, proportion, mean, range) have been 
used to summarize the characteristics of the patients 
before treatment and for monitoring the cytogenetic 
response to therapy. To identify potential prognostic 
factors associated with early and late CCgR Pearson 2 
test has been used. The following levels of statistical 
significance of Pearson 2 test have been used: n.s. 
without statistical significance, 
*
p <0.05, 
**
p <0.01, 
***
p 
<0.001. For the evaluation of the probability of survival 
Kaplan-Meier method has been used.  
Results 
A total of 42 adult patients with newly diagnosed Ph-
positive early chronic phase CML who were treated 
with imatinib have been analysed. The average age of 
patients was 50.52 years (range, 19-73 years) and 22 
patients (52.38%) were female. Significant characteristics 
of the patients before treatment with imatinib are 
presented in Table 1. Median duration of disease from 
diagnosis to initiation of treatment with imatinib therapy 
was 2.5 months (range 1-7 months). The mean follow-
up of patients in this study was 48.4 months (range 32-
90 months) and none of the patients were lost during 
follow-up.  
The rate of cytogenetic response, stability and 
duration of CCgR during the entire study period are 
shown in Table 2. In the study group CCgR has been 
achieved in 85.71% of the analysed patients, while in 
7.14% of patients the absence of cytogenetic response to 
imatinib after more than 1 year of treatment has been 
noted. Patients who achieved CCgR were divided into 
two groups according to the time needed to achieve this 
level of response. Group with early CCgR comprised 
69.44% of the total number of analysed patients, with a 
median time of 6.91.9 months (range 3-12 months) 
needed to accomplish this response. In this group 88% 
of patients achieved CCgR at 6 months, while 12% of 
patients achieved the same response between 6 and 12 
months. Group with late CCgR comprised 30.56% of 
the patients, and the median time from start of treatment 
until CCgR was accomplished was 18.752.4 months 
(range 15-24 months). In this group, 81.82% achieved 
CCgR at 18 months and 18.18% between 18 and 24 
months of treatment with imatinib. Analysis of steadiness 
of CCgR has shown that 84% of the patients in the 
group with early CCgR and 81.81% of the patients in 
the group with late CCgR still maintained stable remission 
without elements of clonal cytogenetic progression during 
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the last control. These results show that there was no 
difference between the groups of patients with early and 
late response in terms of loss of already achieved CCgR.  
Table 1 Clinical and laboratory characteristics of patients 
with chronic myeloid leukaemia before treatment 
with imatinib 
Parameter Mean valuesSD, (range) 
Age, g  50.513.8  (1973) 
Time from diagnosis  
to imatinib, m 
 2.51.7  (17) 
WBC count ×10
9
/L  114.673.8  (20298) 
Platelets ×10
9
/L  395.5230.8  (1401165) 
Haemoglobin, g/dL  118.519.5  (74145) 
Peripheral blasts, %  2.0  (07) 
Peripheral basophils, %  2.8  (09) 
Marrow blasts, %  3.0  (06.5) 
Marrow basophils, %  3.4  (010) 
Splenomegaly, n (%)  29  (69.1) 
Dose, mg, n (%)  
400  30  (71.4) 
600  5  (11.9) 
800   7  (16.7) 
Sokal score, n (%)  
Low  20  (47.7) 
Intermediate  19  (45.2) 
High  3  (7.1) 
Hasford score, n (%)  
Low  27  (64.3) 
Intermediate  12  (28.6) 
High  3  (7.1) 
Table 2 The rate of cytogenetic response to imatinib 
therapy in the analysed period 
 Patients  
Cytogenetic response (CgR) Number (n) % 
Complete CgR, 36/42 85.71 
Early Complete CgR, 25/36 69.44 
Late Complete CgR, 11/36 30.56 
Early response and 
maintenance Complete CgR  
21/25 84.00 
Late response and 
maintenance Complete CgR  
9/11 81.81 
Partial to minimal CgR 3/42 7.14 
Absent CgR 3/42 7.14 
Correlation between the basic characteristics of the 
patients and the subsequent possibility of achieving early 
CCgR have been analysed and presented in Table 3. 
According to statistical analysis out of 12 baseline 
variables 5 of them were identified as prognostic factors 
for achieving early CCgR: less than 5% of marrow blasts, 
less than 5% of marrow basophils, less than 4% of 
peripheral basophils, the absence of peripheral blasts (p 
<0.001), as well as low Hasford risk score (p <0.05).  
Table 3 Prognostic factors associated with early complete 
cytogenetic response  
Characteristics n Early CCgR p  
Age (years)     
<60 31 15 (48.39) 
0.114 n.s. 
≥60  11 10 (90.91) 
Haemoglobin (g/dL)     
<10 16 10 (62.50) 
0.465 n.s. 1011.9 13 9 (69.23) 
≥ 12 13 6 (46.15) 
WBC count (x 10
9
/L)     
<50 9 6 (66.67) 
0.449 n.s. 5099 15 7 (46.67) 
≥ 100 18 12 (66.67) 
Platelets (x 10
9
/L)     
<450 21 14 (66.67) 
0.592 n.s. 450699 16 8 (50.00) 
≥ 700 5 3 (60.00) 
Peripheral blasts (%)     
0% 10 10 (100.0) 
0.001 
*** 
12% 22 13 (59.09) 
≥ 3 % 10 2 (20.00) 
Marrow blasts (%)     
< 5% 36 25 (69.44) 
0.000 
*** 
≥ 5% 6 0   (0.00) 
Peripheral basophils (%)     
< 4% 27 21 (77.78) 
0.001 
*** 
≥ 4% 15 4 (26.67) 
Marrow basophils (%)     
< 5% 33 25 (75.76) 
0.000 
*** 
≥ 5% 9 0   (0.00) 
Splenomegaly (bcm)     
0 13 10 (76.92) 
0.193 n.s. 19 21 12 (57.14) 
≥ 10 8 3 (37.50) 
EUTOS score     
Low  40 25 (62.50) 
0.079 n.s. 
High 2 0 (0.000) 
Hasford score     
Low  27 19 (70.37) 
0.045 
* 
Intermediate  12 6 (50.00) 
High 3 0 (0.00) 
Sokal score     
Low  20 12 (60.00) 
0.081 n.s. Intermediate  19 13 (68.42) 
High 3 0   (0.00) 
*p<0.05 **p<0.01 ***p<0.001  
n.s. without statistical significance, bcm-below costal margin 
Baseline characteristics of patients that are associated 
with the achievement of the late CCgR are shown in Table 
4. Of the 12 pre-treatment characteristics only two have 
been identified as prognostic factors for achieving late 
CCgR: the presence of more than 3% of peripheral blasts 
and value of haemoglobin less than 10g/dL (p <0.05). 
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Table 4 Prognostic factors associated with late complete 
cytogenetic response  
Characteristics  n Late CCgR p  
Age (years)     
<60 31 11 (35.48) 
0.121 n.s. 
≥60  11 0   (0.00) 
Haemoglobin (g/dL)     
<10 16 1   (6.25) 
0.014 
* 
10-11.9 13 3 (23.08) 
≥ 12 13 7 (53.85) 
WBC count (x 10
9
/L)     
<50 9 2 (22.22) 
0.066 n.s. 50 99 15 7 (46.67) 
≥ 100 18 2 (11.11) 
Platelets (x 10
9
/L)     
<450 21 4 (19.05) 
0.425 n.s. 450699 16 6 (37.50) 
≥ 700 5 1 (20.00) 
Peripheral blasts (%)     
0% 10 0   (0.00) 
0.039 
* 
12% 22 6 (27.27) 
≥ 3 % 10 5 (50.00) 
Marrow blasts (%)     
< 5% 36 9 (25.00) 
0.667 n.s. 
≥ 5% 6 2 (33.33) 
Peripheral basophils (%)     
< 4% 27 5 (18.52) 
0.129 n.s. 
≥ 4% 15 6 (40.00) 
Marrow basophils (%)     
< 5% 33 8 (24.24) 
0.582 n.s. 
≥ 5% 9 3 (33.33) 
Splenomegaly (bcm)     
0 13 3 (23.08) 
0.936 n.s. 19 21 6 (28.57) 
≥ 10 8 2 (25.00) 
EUTOS score     
Low  40 10 (25.00) 
0.433 n.s. 
High  2 1 (50.00) 
Hasford score     
Low  27 6 (22.22) 
0.735 n.s. Intermediate  12 4 (33.33) 
High  3 1 (33.33) 
Sokal score     
Low 20 6 (30.00) 
0.783 n.s. Intermediate  19 4 (21.05) 
High  3 1 (33.33) 
*p<0.05   **p<0.01 ***p<0.001 n.s. without statistical 
significance, bcm-below costal margin 
Of the 42 analysed patients 36 are alive, six patients 
died, two in accelerated phase and four due to 
complications with associated diseases. In case of 30 
patients stabile CCgR on the last cytogenetic control was 
maintained and they have been on therapy with imatinib. 
Twelve patients were excluded from imatinib therapy, 
nine were treated with second-generation of tyrosine 
kinase inhibitors, three were treated with interferon plus 
cytarabine. 
 
 
Fig. 1 Kaplan-Meier survival probability in all analysed 
patients (A) and in patients who have achieved 
complete cytogenetic response within 12 months 
or later during treatment with imatinib (B). 
Finally, in this study the survival probability has 
been determined for all patients, both in groups with 
early and late CCgR. Figure 1 shows the estimated 5-
year survival rate for all patients with CCgR (A) and 
(B), namely for patients who achieved this response 
within 1 year or later during treatment (n=25 for early 
response and n=11 for the late response). After 5 years 
of treatment, 77% of patients with CCgR were still alive 
(Fig. 1A). The estimated 5-year overall survival rate 
was 85% in patients with early response and 74% for 
patients with late response (Fig. 1B). 
Discussion 
The introduction of imatinib in CML therapy, a potent 
and selective inhibitor of tyrosine kinase, has led to 
great progress in the treatment of these diseases [10]. 
Most of the available data on the efficacy of imatinib in 
patients with CML is based on the results of the IRIS 
study. This study showed that after an average follow-
up of 54 months, the rate of CHR was 93%, CCgR was 
89%, while the rate of absence of progression was 91%. 
IRIS study has reported the significance of achieving 
cytogenetic response at 12 and 18 months, and that the 
early response at 3 and 6 months was also important 
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[11]. A six-year update of the IRIS study showed that 
the best cumulative rate of CCgR was 82% and the 
estimated overall survival rate after 6 years was 88%-
95% [12]. Results of 8-year IRIS study update [13] once 
again confirmed long-term efficacy and safety of imatinib. 
Clearly, it had been established that the depth of 
response to imatinib therapy was the most important 
prognostic factor for treatment outcome of patients with 
CML [14]. Initial reports suggested the importance of 
achieving cytogenetic response and showed that patients 
without cytogenetic response at 6 months and those with 
minimal cytogenetic response at 12 to 18 months, had a 
worse estimated 4-year survival rate of 70% and 79%, 
compared to those who had a better cytogenetic 
response in whom the estimated 4-year survival rate was 
88% and 100% [15]. Similarly, subsequent analysis has 
again confirmed that the cytogenetic response to 
imatinib at 12 months is indicative of a prognosis. 
Patients who did not achieve CCgR plus PCgR at 12 
months had worse estimated 3-year survival rate than 
the rest, 84% versus 99%. The estimated 5-year survival 
rate for patients achieving CCgR and PCgR at 12 
months was 94% in the both cytogenetic subgroups 
[16]. Analysis of steadiness of CCgR in the study of 
Iacobucci I. et al. [7] showed that in the group of 
patients who achieved CCgR at 12 months, 81% of 
patients continued to maintain stable CCgR at 48 
months of follow-up, while 19% of patients showed a 
loss of response in the same period. It has also been 
demonstrated that there was no difference between the 
groups of patients with early and late response in terms 
of CCgR loss. Similar results were also obtained in this 
study: in patients with early response 84% were still in 
stable CCgR at the last cytogenetic control, while 16% 
of patients showed loss of cytogenetic remission. Our 
data indicate that patients with late response maintained 
stable cytogenetic response of treatment in 81.81%, 
while 18.19% of patients lost CCgR during follow-up.  
Considering that failure regarding achieving CCgR at 
12 months of therapy was associated with a higher risk of 
disease progression, Cardema et al. [17] have analysed 
factors associated with achieving early response. 
Univariate analysis identified the following characteristics 
of patients prior to treatment to be independent poor 
prognostic factors for achieving early CCgR: lower 
haemoglobin, higher percentage of blasts in the peripheral 
blood and bone marrow, splenomegaly and imatinib 
therapy in the standard dose. In the multivariate analysis, 
lower haemoglobin, higher percentage of blasts in the 
peripheral blood and treatment with standard dose 
imatinib, remained as predictors of a decreased 
opportunities for achieving early CCgR on imatinib 
therapy. In this study the results of the correlation between 
the basic characteristics of the patients and the subsequent 
possibility of achieving early CCgR were to some extent 
different. This analysis showed that 5 variables were 
significant predictors of achieving early CCgR: lower 
marrow blasts, lower marrow basophils, lower peripheral 
basophils, the absence of peripheral blasts (p<0.001), as 
well as low Hasford risk score (p<0.05). 
In this study, analysis of the estimated 5-year 
survival has shown that these probabilities in patients 
with early and late CCgR were not significantly 
different. These findings correlate with the results of 
several studies which have confirmed a cytogenetic 
response being important prognostic factor for long-
term outcome of patients with CML. Five-year update 
of the IRIS study showed that progression-free survival 
was better for patients who achieve CCgR regardless of 
whether that response was achieved at 12, 18 or 24 
months, which indicated that the time of achieving 
cytogenetic response was of the lesser importance [3]. 
Similarly, it has been shown that patients treated with 
imatinib who achieved CCgR at 12 months of treatment 
had progression-free survival rate and the estimated 4-
year survival rate similar to those who have not 
achieved CCgR at 12 months [7]. It is worth mentioning 
that there are also reports that showed that among 
patients who achieved CCgR significant differences 
were not observed in the duration of CCgR and disease-
free survival regardless of whether the CCgR has been 
achieved within or after 12 months of imatinib therapy. 
Although patients who did not achieve CCgR can 
improve response during continued imatinib therapy, 
they basically have two options: either to achieve CCgR 
or progress to acceleration phase [17]. 
Conclusion 
Results presented in this paper suggest that among 
patients who achieved CCgR there is no significant 
difference in the rate and duration of CCgR regardless 
of whether they belong to a group with early or late 
response. Analysis of the estimated 5-year survival for 
patients with CCgR has shown similar results in early 
and late responders. All these results indicate that there 
is no difference in the treatment outcome of patients 
with CML in relation to whether the CCgR was 
achieved within or after one year of imatinib therapy. 
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